title: Effective limitation of blood culture use in the burn unit.
abstract: There is little data to support the use of blood culture (BC) testing in the burn patient. Clinical signs (fever, leukocytosis) may not reliably indicate infection; moreover, BC's are expensive, invasive and plagued by false positive results. A policy of critical evaluation of lab utilization was instituted in our burn unit in 1993. By 1997 the use of blood culture testing had decreased by 50%. A retrospective analysis of our change in BC utilization was undertaken to derive practice guidelines for usage of this test.
  
  
  METHODS
  47 patients with BC testing in 1997 were compared to a cohort of 47 patients from 1993, representing a total of 441 BC episodes.
  
  
  RESULTS
  Comparison of 1993 and 1997 patients revealed no significant differences in patient characteristics or outcomes. The mean white blood cell count and maximum temperature on the day of culture were identical for both positive and negative BC episodes. However, BC's drawn during a state of shock were twice as likely to be positive. Patients who experienced positive BC's had larger burns, received more antibiotics, had more indwelling catheters, and had longer lengths of ventilator support and hospital stays.
  
  
  CONCLUSIONS
  Higher patient acuity or the presence of indwelling catheters increases the likelihood of a positive BC. Substantial limitation of BC's without observed changes in length of stay, ventilator days, or mortality suggests that this test can be safely limited without compromising patient outcomes.
authors.affiliation: Intermountain Burn Center, University of Utah, 50 North Medical Drive, Salt Lake City, UT 84132, USA.
authors.forename: Angela
authors.initials: A
authors.lastname: Keen
authors.forename: Lyn
authors.initials: L
authors.lastname: Knoblock
authors.forename: Linda
authors.initials: L
authors.lastname: Edelman
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Saffle
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000175:diagnosis*; D001769:Blood / Q000382:microbiology*; D002056:Burns / Q000150:complications*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D005189:False Positive Reactions; D005260:Female; D006403:Hematologic Tests / Q000706:statistics & numerical data*; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D012189:Retrospective Studies; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents